| CARLAT PUBLISHING

Learning Objectives, Bipolar Disorder, TCPR, November/December 2021

After reading these articles, you should be able to… Read More

How to Treat ADHD in Bipolar Disorder

Are stimulants risky in bipolar disorder? And which is safer – methylphenidate or amphetamine? Chris Aiken, MD, lays out a practical approach to the overlap of bipolar disorder and ADHD. Read More

In the News: Aducanumab (Aduhelm)

When the FDA approved aducanumab (Aduhelm) in Alzheimer dementia, the decision came with a heavy dose of controversy. Rehaz Aziz, MD, considers where this novel therapy fits in practice. Read More

Viloxazine for ADHD

This repurposed antidepressant was recently approved in ADHD, but how does it compare with other treatments? Read More

Listening to Depression: The Importance of Addressing Hearing Loss

A simple intervention improves depression in patients with hearing loss. Read More

Establishing a Dose-Response Relationship for Lurasidone in Acute Schizophrenia

Study suggests we may be underdosing this antipsychotic in schizophrenia. Read More

Sleepwalking on Antipsychotics and Lithium

Sleepwalking is a rare side effect on psychiatric medications, particularly hypnotics and antidepressants. A new analysis explores whether lithium and the antipsychotics should be added to that list. Read More

In Brief: Meds in the Fast Lane

In the last five years, more psychotropics have gained approval through the FDA’s expedited pathways than the slow and cautious routes we’ve grown used to. These “fast-track” and “breakthrough therapy” approvals allow drugs to enter the market on the basis of more efficient (ie, smaller) clinical trials. Read More